宜明凯尔

ImmunoCare is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative cell therapies for oncology and autoimmune diseases. The company focuses on next-generation CAR-T cell products designed to improve clinical outcomes and safety for patients with refractory conditions. Its lead program, IMC-001, is a CD19-targeted CAR-T therapy currently in clinical development for systemic lupus erythematosus (SLE) and various B-cell malignancies. ImmunoCare leverages proprietary manufacturing processes to enhance the scalability and accessibility of its cell-based medicines. The company is supported by prominent venture capital firms and continues to expand its pipeline into multi-target and solid tumor applications.